RxDoctor Payments Data

Alejandro Gonzalez Perez, MD

Family Medicine · Bakersfield, CANPI 1417418179

Payments from drug & device makers

$975in general payments, 2019–2025

Across 39 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$264
  • AbbVie$152
  • Viiv Healthcare Company$118
  • Lilly USA, LLC$101
  • Gilead$49
  • Dynavax Technologies Corporation$44
  • plus $247 from 10 others

What the payments were for

  • Food & beverage$975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$975 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$1,024
Medicare patients
56
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide252$228,893
JardianceEmpagliflozin200$188,553
TrulicityDulaglutide56$52,781
JanuviaSitagliptin Phosphate51$49,157
FarxigaDapagliflozin Propanediol39$39,490
RybelsusSemaglutide22$38,282
EliquisApixaban33$29,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$17,762
XareltoRivaroxaban13$16,614
EntrestoSacubitril/Valsartan21$13,443
Fiasp FlextouchInsulin Aspart (Niacinamide)11$8,059
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$7,833
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$6,652
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$6,320
Atorvastatin Calcium674$4,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$264$267,175274 claims
Boehringer IngelheimJardiance, Stiolto Respimat$30$195,206212 claims
Lilly USA, LLCTrulicity$101$52,78156 claims
MerckJanuvia$41$49,15751 claims
AstraZenecaFarxiga$34$39,49039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →